Observations placeholder
Viibryd
Identifier
020367
Type of Spiritual Experience
Background
A description of the experience
Vilazodone (United States trade name Viibryd ) is a serotonergic antidepressant developed for the treatment of major depressive disorder. Vilazodone was approved by the FDA for use in the United States to treat major depressive disorder in 2011.
Adverse effects
After a one-year, open-label study assessing the safety and tolerability of vilazodone in people with major depressive disorder, the most common adverse effects were diarrhea (35.7%), nausea (31.6%), and headache (20.0%); greater than 90% of these adverse effects were mild or moderate. Whereas in randomized controlled trials these rates were 28%, 23.4% and 13.3%, respectively In contrast to other SSRIs currently on the market, initial clinical trials showed that vilazodone did not cause significant decreased sexual desire/function as with many other antidepressants, which often cause people to abandon their use.
Incidence of adverse effects
Incidence of adverse effects include
Very common adverse effects (incidence >10%)
- Nausea
- Diarrhea
- Headache
Common adverse effects (1-10% incidence)
- Vomiting
- Dry mouth
- Dizziness
- Insomnia
Uncommon adverse effects (0.1-1% incidence)
- Somnolence
- Paraesthesia
- Tremor
- Abnormal dreams
- Libido decreased
- Restlessness
- Akathisia
- Restless legs syndrome
- Abnormal orgasms (male persons only)
- Delayed ejaculations (male persons only)
- Erectile dysfunction (male persons only)
- Fatigue
- Feeling jittery
- Palpitations
- Ventricular premature contractions
- Arthralgia
- Increased appetite
Rare adverse effects (<0.1% incidence)
- Serotonin syndrome — a serious adverse effect characterised by:
- Nausea
- Vomiting
- Mental status change (e.g. confusion, hallucinations, agitation, coma, stupor)
- Muscle rigidity
- Tremor
- Myoclonus
- Hyperreflexia — overresponsive/overactive reflexes
- Hyperthermia — elevated body temperature
- Autonomic instability (e.g. tachycardia, dizziness, abnormally excessive sweating, etc.)
- Mania/hypomania — a potentially dangerously elated/agitated mood. Every antidepressant has the potential to induce these psychiatric reactions. They are particularly problematic in those with a history of hypomania/mania such as those with bipolar disorder
Unknown-incidence adverse effects
- Suicidal ideation — all antidepressants can cause suicidal ideation especially in young
On Dec, 21, 2016 4,514 people reported to have side effects when taking Viibryd.
Among them, 160 people (3.54%) have Hallucination
Time on Viibryd when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 72.34% | 17.02% | 4.26% | 4.26% | 0.00% | 0.00% | 2.13% |
Gender of people who have Hallucination when taking Viibryd :
Female | Male | |
Hallucination | 76.40% | 23.60% |
Age of people who have Hallucination when taking Viibryd :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Hallucination | 0.00% | 0.00% | 3.57% | 12.50% | 19.64% | 17.86% | 8.93% | 37.50% |
Severity of Hallucination when taking Viibryd :
least | moderate | severe | most severe | |
Hallucination | 0.00% | 0.00% | 100.00% | 0.00% |
How people recovered from Hallucination :
while on the drug | after off the drug | not yet | |
Hallucination | 33.33% | 0.00% | 66.67% |
Top conditions involved for these people :
- Depression (44 people, 67.69%)
- Anxiety (8 people, 12.31%)
- Generalised anxiety disorder (4 people, 6.15%)
On Feb, 6, 2016: 1,593 people reported to have side effects when taking Viibryd. Among them, 1 people (0.06%) has Death.
Time on Viibryd when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Viibryd :
Female | Male | |
Death | 0.00% | 100.00% |
Age of people who have Death when taking Viibryd :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
Top conditions involved for these people :
- Major depression (1 people, 100.00%)